These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36844734)

  • 1. Application of rivaroxaban in patients with non-valvular atrial fibrillation and end-stage kidney disease: A systematic review and meta-analysis.
    Yang Z; Wang J; Yuan Y; Cheng T; Ren F; Wang S; Zhang Z
    Front Cardiovasc Med; 2023; 10():1021959. PubMed ID: 36844734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies.
    Qian J; Yan YD; Yang SY; Zhang C; Li WY; Gu ZC
    Front Pharmacol; 2021; 12():642907. PubMed ID: 34211392
    [No Abstract]   [Full Text] [Related]  

  • 6. Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis.
    Zhang J; Tang J; Cui X; Wang B; Bu M; Bai Y; Wang K; Guo J; Shen D; Zhang J
    BMC Cardiovasc Disord; 2019 Jul; 19(1):182. PubMed ID: 31366374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Wang Y; Li L; Wei Z; Lu S; Liu W; Zhang J; Feng J; Wang D
    Medicines (Basel); 2023 Jan; 10(1):. PubMed ID: 36662497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
    Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis.
    Li Z; Zheng Y; Li D; Wang X; Cheng S; Luo X; Wen A
    Anatol J Cardiol; 2022 Jun; 26(6):424-433. PubMed ID: 35703478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
    Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
    ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
    J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anticoagulation in atrial fibrillation patients with intracranial hemorrhage: A systematic review and meta-analysis.
    Zhou Q; Liu X; Yang X; Huang XH; Wu YZ; Tao YY; Wei M
    Front Pharmacol; 2023; 14():1122564. PubMed ID: 36969833
    [No Abstract]   [Full Text] [Related]  

  • 16. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
    Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
    J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of efficacy and safety of new oral anticoagulants compared with warfarin in Japanese patients undergoing catheter ablation for atrial fibrillation.
    Sun Y; Liu X; Xu Y
    J Interv Card Electrophysiol; 2020 Sep; 58(3):381-399. PubMed ID: 32458179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.